Full-length peptide, fragment or acetate? Match the product label to the research before comparing evidence or supplier listings.
TB-500 is not a reliable synonym for full-length thymosin beta-4. In the analytical literature, TB-500 was identified as the seven-amino-acid fragment Ac-LKKTETQ, corresponding to positions 17–23 of the 43-amino-acid parent peptide. Retail listings use the name inconsistently. Check the sequence and chemical form before deciding whether a product matches a paper.
This is a guide to research-material identity and evidence, reviewed September 29, 2026. It does not establish that either material is safe or effective for treating an injury, growing hair, or improving physique.
The 2012 identification study used chromatography and mass spectrometry, then synthesized reference material to confirm the identification. It analyzed a particular product; it was neither a survey of every supplier nor a human treatment trial. The author's later thesis reproduces the analytical work and explains its identity-confirmation methods. Original study, author's thesis, chapter 8.
“17–23” identifies the positions in the parent sequence. Counting both endpoints gives seven residues, not a 17-residue peptide. A shared segment does not make two molecules interchangeable.
The “Ac” attached to the sequence and an acetate salt describe different aspects of identity. A label can refer to an N-acetylated peptide that is also supplied in an acetate salt form. The word “acetate” alone does not tell you whether the peptide is full length or a fragment.
FDA's May 2026 assessment, prepared for its July advisory meeting, separately evaluates TB-500 free base and TB-500 acetate. It also describes inconsistent commercial naming and conflicting identifiers. That is a reason to reconcile the documents, not to choose whichever name sounds more familiar. FDA assessment, pages 7–11.
Ask for the complete sequence, terminal modifications, salt form and batch identifier together. If the product page and certificate disagree, the identity remains unresolved until the supplier or laboratory explains the discrepancy.
Match molecule, formulation, route, population and outcome. Keeping only the shared name discards information that determines what a study can support.
For example, a 2015 randomized trial enrolled 72 adults with dry eye and compared a formulated 0.1% thymosin beta-4 ophthalmic solution with vehicle for 28 days. The two prespecified primary comparisons did not reach statistical significance. Some secondary and additional analyses favored the active formulation. The study concerns a particular eye-drop product and eye outcomes; it does not validate an injectable fragment for tendon repair or hair growth. Its short-term tolerability findings cannot establish long-term safety for a different preparation. Full trial report.
FDA's 2026 assessment reported that its search did not identify human clinical studies of the TB-500 substances it evaluated. Preserve the scope and date of that finding: it is not a claim that no human research exists on full-length thymosin beta-4. The assessment also raises concerns about peptide impurities, aggregation and potential immune reactions. FDA assessment, sections II.C and II.D.
A committee briefing, an advisory discussion and drug approval are different things. The FDA document is an assessment prepared for a compounding advisory meeting, not an approval of a retail product or a personal treatment protocol. Check the FDA meeting materials when evaluating claims about that review.
As checked on September 29, 2026, Swiss Chems maintained separate pages for TB-500 (Thymosin Beta-4) and TB-500 Fragment (17–23). The first described a 43-amino-acid material; the second described the N-acetylated seven-residue sequence. Both listed 10 mg per vial. The equal milligram labels do not make the products chemically equivalent. These are supplier declarations, not results of independent testing by Biomogging. Full-length listing, fragment listing.
For a laboratory procurement comparison, record these fields before comparing prices:
For the separate questions of purity, content and microbiological testing, use our peptide certificate-of-analysis guide. Repeating a supplier's purity claim is not an independent product test.
A useful request is: “For this exact lot, please confirm the full amino-acid sequence, terminal modifications and salt form. Please provide the identity report and explain any mismatch between the product description and certificate, including what the stated milligrams measure.”
Our TB-500 supplier listings provide links to the separately named products. That page contains affiliate links; we may earn a commission on qualifying purchases. Its vendor badges and protocol-based quantities do not establish analytical identity or a validated human regimen. Do not use those quantities as dosing guidance. The listings are for laboratory research materials, not a recommendation to self-treat.
If the question is whether a study supports a health claim, continue with how to check human evidence for research compounds. More documentation can clarify what a material is; it cannot supply missing clinical evidence.
Powered by BTST